Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock

CVS Health (CVS) is trending on Zacks.com, with a recent -4% return compared to the S&P 500's +5.2%. Despite a projected 19.7% YoY decrease in current quarter earnings, consensus estimates forecast a +12.6% increase for the current fiscal year and +14.5% for the next, alongside revenue growth of +3.5% and +4.6% respectively; CVS holds a Zacks Rank #2 (Buy) and a Value Style Score of A, suggesting potential near-term outperformance and undervaluation relative to peers.

Analysis

CVS Health Corporation (CVS) has recently underperformed the broader market and its sector, with shares returning -4% over the past month compared to the S&P 500 composite's +5.2% gain and the Zacks Medical Services industry's -2.7% loss. A key factor influencing near-term performance is earnings expectations: for the current quarter, CVS is expected to post earnings of $1.47 per share, a significant year-over-year decline of -19.7%, and the consensus estimate has been revised downwards by -2.3% over the last 30 days. However, the outlook for the full current fiscal year remains positive with a consensus EPS of $6.10, indicating a +12.6% year-over-year increase, despite a minor -0.2% revision in the last 30 days. Projections for the next fiscal year are stronger, with an expected EPS of $6.98, representing a +14.5% increase, and this estimate has seen a positive revision of +2.2% over the past month. Revenue growth is also anticipated, with a +3% year-over-year increase to $93.93 billion projected for the current quarter, and +3.5% and +4.6% growth for the current and next fiscal years, respectively. CVS demonstrated strong past performance, reporting revenues of $94.59 billion (+7% YoY) and EPS of $2.25 in its last quarter, surpassing consensus estimates by +1.76% and +31.58% respectively, and has beaten EPS estimates in each of the trailing four quarters. Reflecting these dynamics, CVS holds a Zacks Rank #2 (Buy) and a Zacks Value Style Score of A, suggesting it is trading at a discount relative to peers and may outperform in the near term.

Key Decisions for Investors

• Investors should consider the potential buying opportunity indicated by CVS Health's Zacks Rank #2 (Buy) and its Value Style Score of A, which suggests undervaluation despite the recent share price decline of -4% in the past month.
• It is crucial to monitor the upcoming quarterly earnings, particularly the forecasted -19.7% year-over-year EPS decrease, as this will be a key test of the company's resilience against the backdrop of positive full-year (+12.6%) and next fiscal year (+14.5%) EPS growth projections.
• The positive +2.2% revision in consensus EPS estimates for the next fiscal year and a strong history of earnings beats should be weighed against the immediate earnings pressure and the minor recent negative revision for the current fiscal year's EPS.